Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
Caribou Biosciences (Nasdaq: CRBU) will host a live webcast at 8:00 am ET on Monday, November 3, 2025 to report new clinical data.
The presentation will cover updated results from the ANTLER Phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010) in relapsed or refractory B cell non-Hodgkin lymphoma and the first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The company will also outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011 development.
A live webcast is available on Caribou’s Events page and the archived webcast will be accessible for 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) trasmetterà in diretta una webcast alle 8:00 am ET di lunedì 3 novembre 2025 per riferire nuovi dati clinici.
La presentazione includerà i risultati aggiornati dal ANTLER Phase 1 trial di vispacabtagene regedleucel (vispa-cel; precedentemente CB-010) in linfoma non-Hodgkin B recidivante o refrattario e i primi dati clinici dal CaMMouflage Phase 1 trial di CB-011 in mieloma multiplo ricidivante o refrattario. L’azienda descriverà anche il previsto design del trial fondamentale di fase 3 per vispa-cel e i prossimi passi per lo sviluppo di CB-011.
Una webcast in diretta è disponibile sulla pagina Eventi di Caribou e la webcast archiviata sarà accessibile per 30 giorni dopo l’evento.
Caribou Biosciences (Nasdaq: CRBU) celebrará una webcast en vivo a las 8:00 am ET del lunes 3 de noviembre de 2025 para presentar nuevos datos clínicos.
La presentación cubrirá los resultados actualizados del ensayo de Fase 1 ANTLER de vispacabtagene regedleucel (vispa-cel; anteriormente CB-010) en linfoma de células B no Hodgkin recidivado o refractario y los primeros datos clínicos del ensayo de Fase 1 CaMMouflage de CB-011 en mieloma múltiple recidivado o refractario. La compañía también esbozará su diseño anticipado del ensayo pivotal de Fase 3 para vispa-cel y los próximos pasos para el desarrollo de CB-011.
Una webcast en vivo está disponible en la página de Eventos de Caribou y la webcast archivada estará disponible durante 30 días después del evento.
Caribou Biosciences (나스닥: CRBU)는 새로운 임상 데이터를 보고하기 위해 2025년 11월 3일 월요일 동부 표준시 8:00에 생방송 webcast를 주최합니다.
발표는 vispacabtagene regedleucel(Vispa-cel, 이전 CB-010)의 ANTLER 1상 임상시험의 업데이트된 결과와 재발 또는 불응 B세포 비호지킨 림프종에서의 CaMMouflage 1상 임상시험의 CB-011의 첫 임상 데이터를 다룰 예정입니다. 또한 vispa-cel의 결정적 3상 시험 설계와 CB-011 개발의 향후 단계도 개요로 제시됩니다.
생방송 webcast는 Caribou의 이벤트 페이지에서 이용 가능하며 이벤트 이후 30일 동안 보관된 녹화분에 접근할 수 있습니다.
Caribou Biosciences (Nasdaq: CRBU) organisera une webcast en direct à 8 h 00 ET le lundi 3 novembre 2025 pour communiquer de nouvelles données cliniques.
La présentation couvrira les résultats actualisés de l’essai ANTLER Phase 1 de vispacabtagene regedleucel (vispa-cel; anciennement CB-010) chez les lymphomes B non hodgkiniens récurrents ou réfractaires et les premiers données cliniques de l’essai CaMMouflage Phase 1 de CB-011 chez le myélome multiple récurrent ou réfractaire. La société décrira également son design anticipé de l’essai pivot de phase 3 pour vispa-cel et les prochaines étapes pour le développement de CB-011.
Une webcast en direct est disponible sur la page Événements de Caribou et la webcast enregistrée sera accessible pendant 30 jours après l’événement.
Caribou Biosciences (Nasdaq: CRBU) wird eine Live-Webcastveranstaltung um 8:00 Uhr ET am Montag, dem 3. November 2025 abhalten, um neue klinische Daten zu berichten.
Die Präsentation wird aktualisierte Ergebnisse aus der ANTLER Phase 1-Studie von vispacabtagene regedleucel (vispa-cel; vormals CB-010) bei relapse oder refraktärem B-Zell-Nicht-HN-Lymphom sowie die ersten klinischen Daten aus der CaMMouflage Phase 1-Studie von CB-011 bei rekidivierendem oder refraktärem multiplem Myelom behandeln. Das Unternehmen skizziert zudem sein erwartetes Entwurf des pivotalen Phase-3-Studienplans für vispa-cel und die nächsten Schritte zur Entwicklung von CB-011.
Eine Live-Webcast ist auf der Veranstaltungen-Seite von Caribou verfügbar und die archivierte Webcast wird 30 Tage nach der Veranstaltung zugänglich sein.
Caribou Biosciences (ناسداك: CRBU) ستستضيف بثًا حيًا مباشرًا في الساعة 8:00 صباحًا بتوقيت شرق الولايات المتحدة يوم الإثنين 3 نوفمبر 2025 للإبلاغ عن بيانات سريرية جديدة.
سيغطي العرض نتائج مُحدّثة من تجربة ANTLER المرحلة 1 ل vispacabtagene regedleucel (vispa-cel؛ سابقاً CB-010) في الورم اللمفي البیوني من نوع B المتكرر أو المقاوم وبيانات سريرية أولية من تجربة CaMMouflage المرحلة 1 لـ CB-011 في الورم النخامي المتكرر أو المقاوم. ستوضح الشركة أيضًا تصميم تجربة المرحلة الحاسمة من المرحلة 3 لـ vispa-cel والخطوات التالية لتطوير CB-011.
يمكن الوصول إلى البث المباشر من صفحة فعاليات Caribou وسيكون البث المسجّل متاحًا لمدة 30 يومًا بعد الحدث.
- None.
- None.
BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and report the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011, an allogeneic anti-BCMA CAR-T cell therapy, in patients with r/r multiple myeloma. The Company will also report its anticipated pivotal phase 3 trial design for vispa-cel and next steps for the continued clinical development of CB-011.
A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.
About vispacabtagene regedleucel
Vispacabtagene regedleucel (vispa-cel; formerly known as CB-010) is an allogeneic anti-CD19 CAR-T cell therapy being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). To Caribou’s knowledge, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL. Additional information on the ANTLER trial (NCT04637763) can be found at clinicaltrials.gov.
About CB-011
CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage Phase 1 trial. To Caribou’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection. CB-011 has been granted Fast Track and Orphan Drug designations by the FDA. Additional information on the CaMMouflage trial (NCT05722418) can be found at clinicaltrials.gov.
About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the Company @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com
FAQ
When will Caribou Biosciences (CRBU) present the new ANTLER and CaMMouflage data?
What data will Caribou report for vispa-cel (CB-010) on November 3, 2025?
What first clinical data will CRBU present for CB-011 on the webcast?
How can investors access Caribou's November 3, 2025 webcast and replay?
Will the webcast include development plans beyond the Phase 1 data for CRBU programs?
